Affy, Agilent, Illumina Affirm Commitment to Array Market in Light of Roche's Planned Exit | GenomeWeb

Seeking to calm any researchers jittery about the future of the array market, representatives for Affymetrix, Agilent Technologies, and Illumina this week all vowed to continue to make microarrays and opened their arms to researchers displaced by Roche's recent decision to shutter or sell its NimbleGen array business.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: CRISPR-based barcodes to trace cell lineages, and more.

The director of the National Institutes of Health Francis Collins sang the national anthem this week before a baseball game.

French researchers criticize unexpected government plan to cut research funding, ScienceInsider reports.

In Nature this week: genetic mechanism through which some cancers evade the immune system, and more.